Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

Breaking & Recent News Prelude Therapeutics Inc PRLD

Prelude Therapeutics Incorporated is a clinical-stage fully integrated oncology company built on a foundation of drug discovery to deliver novel precision cancer medicines to underserved patients. It has developed a diverse pipeline consisting of multiple distinct programs: kinases, targeted protein degraders, and precision antibody drug conjugates. Its product candidates include PRT3789... see more

Recent & Breaking News (NDAQ:PRLD)

Prelude Therapeutics to Participate in Upcoming Healthcare Conferences

GlobeNewswire June 2, 2025

Prelude Therapeutics Reports First Quarter 2025 Financial Results and Provides Corporate Update

GlobeNewswire May 6, 2025

Prelude Therapeutics to Participate in Citizens Life Sciences Conference

GlobeNewswire May 1, 2025

Prelude Announces Presentations at 2025 AACR Annual Meeting

GlobeNewswire April 25, 2025

Prelude Therapeutics Reports Full Year 2024 Financial Results and Provides Program Outlook for 2025

GlobeNewswire March 10, 2025

Prelude Therapeutics to Participate in Barclays 27th Annual Global Healthcare Conference

GlobeNewswire March 5, 2025

Prelude Therapeutics Presents Preliminary Results of Phase 1 Dose-escalation Study of PRT2527 as Monotherapy and in Combination with Zanubrutinib in Patients with Relapsed/Refractory Lymphoid Malignancies

GlobeNewswire December 11, 2024

Prelude Therapeutics to Participate in Citizens JMP Securities Hematology and Oncology Summit

GlobeNewswire November 27, 2024

Prelude Therapeutics Reports Third Quarter 2024 Financial Results and Provides Corporate Update

GlobeNewswire November 6, 2024

Prelude Therapeutics Presents New Data from SMARCA Degrader Portfolio at the 36th EORTC-NCI-AACR Symposium

GlobeNewswire October 24, 2024

Prelude Therapeutics Announces Publication of Abstracts for Presentation at the 36th EORTC-NCI-AACR Symposium

GlobeNewswire October 9, 2024

Prelude Therapeutics' SMARCA2 Degrader PRT3789 Demonstrated Promising Initial Clinical Activity and Safety Profile in Phase 1 Trial

GlobeNewswire September 13, 2024

Prelude Therapeutics Announces Publication of Abstract for Presentation at the European Society of Medical Oncology (ESMO) Congress 2024

GlobeNewswire September 9, 2024

Prelude Therapeutics Reports Second Quarter 2024 Financial Results and Provides Corporate Update

GlobeNewswire August 12, 2024

Prelude Therapeutics Announces Clinical Collaboration with Merck to Evaluate PRT3789 in Combination with KEYTRUDA® (pembrolizumab) in Patients with SMARCA4-Mutated Cancers

GlobeNewswire July 9, 2024

Prelude Therapeutics to Participate in Upcoming Healthcare Conferences

GlobeNewswire June 3, 2024

Prelude Therapeutics to Participate in Citizens JMP Life Sciences Conference

GlobeNewswire May 9, 2024

Prelude Therapeutics Reports First Quarter 2024 Financial Results and Provides Corporate Update

GlobeNewswire May 7, 2024

Prelude Highlights Continued Strength of Discovery Engine at 2024 AACR Annual Meeting

GlobeNewswire April 9, 2024

Prelude Announces Acceptance of Multiple Preclinical Abstracts at the 2024 AACR Annual Meeting

GlobeNewswire March 5, 2024